Clinical Trials
20 trialsNCT03947385 2026-01-27
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT01991379 2025-12-04
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT03106415 2025-06-27
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04494958 2025-03-24
PALBOBIN
Fundacion Oncosur
Phase 1/2 Completed
NCT05340621 2025-03-07
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
OnKure, Inc.
Phase 1/2 Completed
NCT03843775 2024-10-21
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT01543698 2024-03-13
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Pfizer
Phase 1/2 Completed
NCT04720768 2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT03637491 2022-01-26
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown
NCT01927341 2021-02-18
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Pfizer
Phase 1/2 Completed
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed
NCT01562899 2020-12-10
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01801358 2020-09-16
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Array BioPharma
Phase 1/2 Terminated
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed